Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 30, 2015 12:20 ET | Source: AB Science

AB Science Announces Positive Top-Line Results from Phase 3 Trial of Masitinib in Adults with Severe Systemic Mastocytosis

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Paris, 30 November 2015, 6.15pm AB Science...
November 06, 2015 09:39 ET | Source: AB Science

AB Science : Information mensuelle relative au nombre total de droits de vote et d'actions

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} AB SCIENCE S.A.Société Anonyme au capital de...
October 06, 2015 12:27 ET | Source: AB Science

AB Science: unblinding of phase 3 mastocytosis study data planned for November 2015

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Paris, 06 October 2015, 6pm Simulations...
October 06, 2015 12:27 ET | Source: AB Science

AB Science : levée de l'insu des résultats de l'étude de phase 3 dans la mastocytose prévue pour novembre 2015

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Paris, 6 octobre 2015, 18h Les...
September 21, 2015 12:06 ET | Source: AB Science

AB Science announces cessation of its rheumatoid arthritis study in order to focus on clinical studies with a probability of success greater than 50%

PARIS, Sept. 21, 2015 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors...
September 21, 2015 11:59 ET | Source: AB Science

AB Science announces cessation of its rheumatoid arthritis study in order to focus on clinical studies with a probability of success greater than 50%

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Paris, 21 September 2015, 17h45 AB Science...
September 21, 2015 11:59 ET | Source: AB Science

AB Science annonce l'arrêt de l'étude clinique dans la polyarthrite rhumatoïde afin de se concentrer sur les études ayant une probabilité de succès supérieure à 50%

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Paris, 21 septembre 2015, 17h45 AB Science...
September 16, 2015 12:07 ET | Source: AB Science

AB Science: Masitinib Receives Orphan Drug Designation for Stomach Cancer from FDA

PARIS, Sept. 16, 2015 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors...
September 16, 2015 12:04 ET | Source: AB Science

AB Science: Masitinib Receives Orphan Drug Designation for Stomach Cancer from FDA

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Paris, 16 September 2015, 6pm Masitinib...
September 16, 2015 12:04 ET | Source: AB Science

AB Science : le masitinib obtient la désignation de médicament orphelin auprès de la FDA dans le traitement du cancer de l'estomac

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Paris, 16 septembre 2015, 18h Le masitinib...